Evidence map›Paper›PMID 24844798›Full record

ArticleNature communications2014

Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice.

Roman L Bogorad, Hao Yin, Anja Zeigerer, Hidenori Nonaka, Vera M Ruda, Marino Zerial, Daniel G Anderson, Victor Koteliansky

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Roman L Bogorad1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [2].
Hao Yin1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [2].
Anja ZeigererMax Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.
Hidenori NonakaMax Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.
Vera M RudaDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Marino ZerialMax Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.
Daniel G Anderson1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [2] Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [3] Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts 02139, USA [4] Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Victor Koteliansky1] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [2] Skolkovo Institute of Science and Technology, ul. Novaya, d.100, Skolkovo 143025, Russian Federation.
Massachusetts Institute of Technology · USMax Planck Institute of Molecular Cell Biology and Genetics · DESkolkovo Institute of Science and Technology · RU

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
High-Throughput Craniofacial tissue engineeringR01DE016516 · NIDCR · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2005 to 2014
$3.8M
NCI NIH HHS P30 CA014051NIDCR NIH HHS NIH RO1-DE016516NIDCR NIH HHS R01 DE016516PHS HHS P30CCA14051
6 · The paper itself

Abstract

Integrins play an important role during development, regulating cell differentiation, proliferation and survival. Here we show that knockdown of integrin subunits slows down the progression of hepatocellular carcinoma (HCC). Using nanoparticulate delivery of short interfering RNAs targeting β1 and αv integrin subunits, we downregulate all integrin receptors in hepatocytes. Short-term integrin knockdown (2 weeks) does not cause apparent structural or functional perturbations of normal liver tissue. Alterations in liver morphology accumulate on sustained integrin downregulation (7 weeks). The integrin knockdown leads to significant retardation of HCC progression, reducing proliferation and increasing tumour cell death. This tumour retardation is accompanied by reduced activation of the MET oncogene as well as expression of its mature form on the cell surface. Our data suggest that transformed proliferating cells from HCC are more sensitive to knockdown of integrins than normal quiescent hepatocytes, highlighting the potential of small interfering RNA-mediated inhibition of integrins as an anti-cancer therapeutic approach.

Indexed as

NanoparticlesRNA, Small InterferingAnimalsCarcinoma, HepatocellularCell ProliferationDisease ProgressionDown-RegulationGene Knockdown TechniquesHepatocytesIntegrin alpha ChainsIntegrin beta ChainsLiver Neoplasms, ExperimentalMiceProto-Oncogene Proteins c-metIntegrin alpha ChainsIntegrin beta ChainsProto-Oncogene Proteins c-metRNA, Small Interfering

Identifiers

PMID24844798
PMCPMC4107318
OpenAlexW2027693306

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.